Median PFS was @ months ( @ % CI @-@ ) in the group assigned to mFOLFOX@ plus bevacizumab and @ months ( @-@ ) in the group assigned to SOX plus bevacizumab ( HR @ , @ % CI @-@ ; less than non-inferiority margin of @ , pnon-inferiority = @ ) .